Literature DB >> 12359502

Targeted mutations of the corticotropin-releasing factor system: effects on physiology and behavior.

A Contarino1, L H Gold.   

Abstract

Genetic modifications of the genes that encode proteins integral to the corticotropin-releasing factor (CRF) system have been employed in the creation of mutant mice that serve as tools for studying the role of this neuropeptide in regulated and dysregulated behaviors and physiology. Overexpression of the CRF peptide and CRF binding protein as well as deletion of the peptide, binding protein, and both known receptors has been achieved and these mouse models have been characterized for anatomical, neuroendocrine, and behavioral sequelae. The profile of results, consistent with current knowledge of CRF function from more traditional assays, indicates that enhancement of CRF function is associated with an activation of the hypothalamic-pituitary-adrenal axis, an anxious phenotype, alterations in cognitive performance and reductions in feeding. In general, blockade of CRF function produces the opposite effects. Genetic mouse models allow further analysis of specific elements in the CRF circuitry for which more traditional tools have not existed. These animal models are valuable for increasing our understanding of the underlying pathology associated with a variety of psychiatric and neuroendocrine disorders and for the development and testing of novel treatment agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359502     DOI: 10.1054/npep.2002.0899

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  9 in total

1.  Role of the corticotropin-releasing factor receptor type 2 in the control of food intake in mice: a meal pattern analysis.

Authors:  A Tabarin; Y Diz-Chaves; D Consoli; M Monsaingeon; T L Bale; M D Culler; R Datta; F Drago; W W Vale; G F Koob; E P Zorrilla; A Contarino
Journal:  Eur J Neurosci       Date:  2007-10       Impact factor: 3.386

2.  Polymorphism in the corticotropin-releasing factor receptor 1 (CRF1-R) gene plays a role in shaping the high anxious phenotype of Marchigian Sardinian alcohol-preferring (msP) rats.

Authors:  Andrea Cippitelli; Lydia O Ayanwuyi; Estelle Barbier; Esi Domi; Jose M Lerma-Cabrera; Francisca Carvajal; Giulia Scuppa; Hongwu Li; Massimo Ubaldi; Markus Heilig; Marisa Roberto; Roberto Ciccocioppo
Journal:  Psychopharmacology (Berl)       Date:  2014-09-27       Impact factor: 4.530

3.  CRF1 receptor-deficiency induces anxiety-like vulnerability to cocaine.

Authors:  Nadège Morisot; Mark J Millan; Angelo Contarino
Journal:  Psychopharmacology (Berl)       Date:  2014-04-01       Impact factor: 4.530

4.  Emotional behavior in aged neuropeptide Y (NPY) Y2 knockout mice.

Authors:  Cristina Carvajal; Yvan Dumont; Herbert Herzog; Rémi Quirion
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 5.  Prenatal corticosteroid impact on hippocampus: implications for postnatal outcomes.

Authors:  Libor Velísek
Journal:  Epilepsy Behav       Date:  2005-08       Impact factor: 2.937

6.  Disruption of the CRF(2) receptor pathway decreases the somatic expression of opiate withdrawal.

Authors:  Francesco Papaleo; Sandy Ghozland; Manuela Ingallinesi; Amanda J Roberts; George F Koob; Angelo Contarino
Journal:  Neuropsychopharmacology       Date:  2008-02-20       Impact factor: 7.853

7.  Ghrelin, appetite regulation, and food reward: interaction with chronic stress.

Authors:  Yolanda Diz-Chaves
Journal:  Int J Pept       Date:  2011-09-21

8.  The Relationship between Ghrelin and Copeptin Levels, and Anxiety and Depression Levels in Suicide Attempts.

Authors:  Metin Atescelik; Mustafa Yilmaz; Sevda Korkmaz; Mehmet Cagri Goktekin; Mehtap Gurger; Nevin Ilhan
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-08-31       Impact factor: 2.582

9.  Usefulness of a Kampo Medicine on Stress-Induced Delayed Gastric Emptying in Mice.

Authors:  Sachiko Mogami; Ryutaro Arita; Miwa Nahata; Naoki Fujitsuka; Shin Takayama; Tadashi Ishii
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-31       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.